Asacol®

DRUG3 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., Tillotts Pharma AG

Conditions

Active Ulcerative ColitisUlcerative ColitisUlcerative Colitis in Remission

Phase 3

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

CompletedNCT00092508

Otsuka Pharmaceutical Development & Commercialization, Inc.Ulcerative Colitis

Start: 2004-05-31End: 2007-05-31Target: 1725Updated: 2007-06-21

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

CompletedNCT01257386

Tillotts Pharma AGActive Ulcerative Colitis

Start: 2010-11-30End: 2013-03-31Updated: 2013-04-04

Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

CompletedNCT01257399

Tillotts Pharma AGUlcerative Colitis in Remission

Start: 2010-11-30End: 2013-03-31Updated: 2013-04-04

Related Papers

Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.

2016-02-237 citations

Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.

2016-02-222 citations